Aging Mammary Stem Cells and Breast Cancer Prevention

Summary

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens

Timeline

Start

2016-07

Primary completion

2022-03-01

Completion

2022-05-01

Outcome

Mixed primary results

Stopped: “The study was terminated early according to the protocol due to efficacy.”

registry MEAN Control: 3.681 (Standard Deviation 2.303) spheres formed per 1,000 cells NCT02642094 ↗

registry MEAN Treatment Group: 0.717 (Standard Deviation 1.414) spheres formed per 1,000 cells NCT02642094 ↗

registry analysis (superiority test); Control vs Treatment Group; p <0.0001; t-test, 2 sided NCT02642094 ↗

registry analysis (superiority test); Control vs Treatment Group; p = 0.3093; t-test, 2 sided NCT02642094 ↗

Publications

• Bouamar H, Broome LE, Lathrop KI, Jatoi I, Brenner AJ, Nazarullah A, Gorena KM, Garcia M, Chen Y, Kaklamani V, Sun LZ. mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers. Breast Cancer Res. 2023 Oct 30;25(1):131. doi: 10.1186/s13058-023-01727-z.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rapamycin	Small molecule	2 mg	—

Indications